Ciloa presented its unique technology for producing membrane proteins from cells at the BioEurope conference held in Munich, Germany.
Biotech companies showed keen interest in Ciloa technology for obtaining the membrane proteins of their choice to develop therapeutical products. The key appeal of the Ciloa solution is that it offers truly native GPCR on exosomal nanovesicles.
The use of Surface Plasmon Resonance (SPR) to detect interactions of chemokine and monoclonal antibodies with non-labeled GPCR represents a technological disruption that has the potential to significantly increase efficiency for biotech firms. Identifying GPCR-ligand interactions and accessing their affinity constants at the same time open the door for easier development of therapeutic ligands.